As point-of-care testing solution that can help healthcare providers expedite diagnosis and treatment of anemia in children and adolescents, Pronto-7® enables noninvasive spot-checking of total hemoglobin (SpHb®), SpO2, pulse rate, and perfusion index. Embedded 802.11 b/g and Bluetooth capabilities enable wireless printing or emailing of test results. With dimensions of 5.1 x 2.8 x 1 in., 10.5 oz instrument also offers Max Sensitivity Mode and can measure hemoglobin in less than 1 min. IRVINE, Calif. — Masimo (NASDAQ: MASI) today announced FDA 510(k) clearance and full market commercial launch of the Masimo Pronto-7®–a palm-sized handheld device designed for quick and easy noninvasive spot-checking of total hemoglobin (SpHb®), SpO2, pulse rate, and perfusion index. Hailed as a “potential game-changing technology,” Dr. Andrew J. Schuman–adjunct assistant professor of pediatrics at Dartmouth Medical School, contributing editor for Contemporary Pediatrics, and a practicing pediatrician in New Hampshire, who reviewed the device prior to FDA clearance–says that the new Pronto-7 is so innovative it has the “potential for significantly improv...